UK markets closed

WuXi Biologics (Cayman) Inc. (2269.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
113.100-3.600 (-3.08%)
At close: 4:08PM HKT

WuXi Biologics (Cayman) Inc.

No. 108, Meiliang Road
Mashan Binhu District
Wuxi 214092
China

http://www.wuxibiologics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees7,686

Key executives

NameTitlePayExercisedYear born
Dr. Ge LiFounder & ChairmanN/AN/A1967
Dr. Zhisheng ChenCEO & Exec. Director699.75kN/A1973
Dr. Weichang ZhouExec. VP, CTO & Exec. Director374.6kN/A1964
Ms. Shaohua Lu-WongCo-CFO & Exec. VPN/AN/A1969
Mr. Ming TuCo-CFO & Exec. VPN/AN/A1968
Dr. Jijie GuExec. VP & Chief Scientific OfficerN/AN/A1966
Ms. Eileen WangIR Sr. DirectorN/AN/AN/A
Ms. Tang Shaogui M.B.A.VP and Head of Global Corp. Communications & Public AffairsN/AN/AN/A
Ms. Michelle M. Chen Ph.D.VP & Head of Corp. Devel.N/AN/AN/A
Mr. Angus Scott Marshall TurnerSr. VP of Global Bus. Devel. & Alliance ManagementN/AN/A1968
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd. The company was incorporated in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.

Corporate governance

WuXi Biologics (Cayman) Inc.’s ISS governance QualityScore as of 26 September 2021 is 2. The pillar scores are Audit: 4; Board: 8; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.